The relationship between dose and antihypertensive effect for different AT1-receptor blockers

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypertension management is crucial for preventing cardiovascular complications.
• Angiotensin II type I (AT1)-receptor blockers offer effective blood pressure control with good tolerability.
• Previous meta-analyses comparing AT1-receptor blockers have limitations due to trial inconsistencies and lack of primary data access.

Purpose of the Study:

• To compare the antihypertensive efficacy of different AT1-receptor blockers.
• To highlight the importance of head-to-head studies for accurate drug comparison.
• To emphasize the need for up-to-date data and placebo effect correction.

Main Methods:

• Review of randomized, prospective, double-blind, head-to-head comparative studies.
• Analysis of blood pressure reduction and maintenance of antihypertensive efficacy.
• Consideration of dose-response relationships and placebo effect adjustments.

Main Results:

• Candesartan cilexetil and irbesartan demonstrated superior efficacy compared to losartan.
• These drugs showed greater reduction in blood pressure.
• Antihypertensive efficacy was better maintained between doses with candesartan cilexetil and irbesartan.

Conclusions:

• Randomized, head-to-head trials are the gold standard for comparing antihypertensive drug efficacy.
• Candesartan cilexetil and irbesartan are more effective than losartan in managing hypertension.
• Accurate comparison requires up-to-date studies and correction for placebo effects.